Last update 21 Nov 2024

Venlafaxine Hydrochloride

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryVenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), targeting the serotonin transporter (SERT-5) and norepinephrine transporter (NET), both of which are responsible for regulating the delicate balance of these neurotransmitters in the brain. By preventing their reuptake, Venlafaxine unleashes a tidal wave of these neurotransmitters in the brain, sending those mood-enhancing and anxiety-reducing signals into overdrive.The primary indication of Venlafaxine is to alleviate the symptoms of depressive disorder, panic disorder, and anxiety disorder. On December 28, 1993, the FDA approved Wyeth Corp's Venlafaxine . Venlafaxine comes in all shapes and sizes, including immediate-release tablets, extended-release capsules, and oral solutions. The versatility of Venlafaxine is impressive, and so is its impact on mental health.

Drug Type

Small molecule drug

Synonyms

Dobupal, Efexor XR, Effexor SR

+ [27]

Target

NET x SERT

Mechanism

NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors

Therapeutic Areas

Other Diseases

Active Indication

Anxiety DisordersDepressive Disorder, MajorPanic Disorder+ [3]

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Upjohn US 2 LLCBGP Pharma ULC

Viatris, Inc.

+ [4]

Inactive Organization

Pfizer Inc.Wyeth ABWyeth Canada ULC

+ [2]

Drug Highest PhaseApproved

First Approval Date

US (28 Dec 1993),

Depressive Disorder

RegulationPriority Review (CN)

Structure

Molecular FormulaC17H28ClNO2

InChIKeyQYRYFNHXARDNFZ-UHFFFAOYSA-N

CAS Registry99300-78-4

View All Structures (2)

185

Clinical Trials associated with Venlafaxine Hydrochloride

TCTR20240706012 / Not yet recruitingPhase 1IIT

A randomized, open-labeled, multiple-dose, two-way crossover design with two-period, two-treatment, two-sequence steady-state bioequivalence study of Venlafaxine Hydrochloride Extended-Release Capsules 150 mg and Efexor XR 150 mg Capsules in healthy, adult, Thai volunteers under fed condition

Start Date20 May 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

TCTR20240706010 / Not yet recruitingPhase 1IIT

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Venlafaxine Hydrochloride Extended-Release Capsules 150 mg and Efexor XR 150 mg Capsules in healthy, adult, Thai volunteers under fed condition

Start Date13 May 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

TCTR20240705003 / Not yet recruitingPhase 1IIT

Start Date05 May 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

100 Clinical Results associated with Venlafaxine Hydrochloride

100 Translational Medicine associated with Venlafaxine Hydrochloride

100 Patents (Medical) associated with Venlafaxine Hydrochloride

4,663

Literatures (Medical) associated with Venlafaxine Hydrochloride

01 Jan 2025·Biosensors and Bioelectronics

Field-deployable pencil lead-based electrochemical cell for the determination of the emerging contaminant and antidepressant drug venlafaxine in wastewater

Article

Author: Fernández-Abedul, M Teresa ; Fernández-Abedul, M. Teresa ; Rioboó-Legaspi, Pablo ; Cerrato-Alvarez, Maria ; Costa-Rama, Estefania ; Fernández-Abedul, M.Teresa

Screening and quantification of emerging contaminants in water is of enormous relevance due to its scarcity and harmful effects on aquatic life and human health. We present a simple and cost-effective electrochemical cell for determination of the antidepressant venlafaxine, an emerging contaminant included in the EU Watch list 2022. The cell consists of pencil leads used as electrodes and a microcentrifuge tube. Modification of the working electrode with carbon nanomaterials improved the signal. Cell-related (e.g., type of pencil leads or electroactive area) as well as experimental (e.g., pH, accumulation potential and time, and scan rate) parameters were thoroughly optimized. The adsorptive nature of venlafaxine process allowed the use of an adsorptive stripping square wave voltammetry methodology to increase the sensitivity. Under optimized variables, a linear range from 0.8 to 10 μmol L^-1 with a correlation coefficient of 0.996, a sensitivity of 1.48 μmol L^-1, a LOD of 0.4 μmol L^-1 and a RSD of 2.4 % were achieved. Selectivity was also studied, especially with respect to the main metabolite, o-desmethylvenlafaxine. The methodology distinguishes its signal from that of the main compound, allowing its determination. A similar linear range was obtained for the metabolite, with a LOD of 0.6 μmol L^-1. The platform developed was applied for venlafaxine quantification in spiked wastewaters from the Febros plant in Portugal, obtaining satisfactory recoveries. Furthermore, the versatility of pencil leads made it possible to combine them with modified paper for sampling and buffering in order to decentralize the determination, showing promising results.

01 Jan 2025·Journal of Clinical Densitometry

Comparison of the Effect of Selective Serotonin and Norepinephrine Reuptake Inhibitors on Bone Mineral Density with Selective Serotonin Reuptake Inhibitors and Healthy Controls

Article

Author: Ak Aygün, Emine ; Zengin İspir, Gamze ; AYGÜN, Emine AK ; AK Aygün, Emine ; BULUT, Serdar ; ZENGİN İSPİR, Gamze ; Bulut, Serdar ; BULUT, Süheyla DOĞAN ; Doğan Bulut, Süheyla

PURPOSEThis study investigated the association between selective serotonin reuptake inhibitor (SSRI) and selective serotonin and norepinephrine reuptake inhibitor (SNRI) use and the risk of decreased bone mineral density in postmenopausal women.METHODSSixty-three patients diagnosed with GAD (Generalized Anxiety Disorder) were treated with venlafaxine or duloxetine from the SNRI group, and sixty patients treated with SSRIs were enrolled. Social demographic features, the Hamilton Anxiety Scale (HAS) results, and the Hamilton Depression Scale (HDS) scores of all the patients were assessed. The BMD (bone mineral density) of the patients was measured by dual-energy X-ray absorptiometry (DXA) at the femoral and lumbar regions. The BMD of the patients was compared with that of 40 healthy controls.RESULTSBone measurements in the SNRI and SSRI users were similar to those of the healthy controls. However, osteopenic values were observed in the SSRI users, while normal bone density was found in the SNRI users. Also, the bone mineral densities were compared between patients using duloxetine and venlafaxine with healthy controls, showing similar T-score and Z-score values with no significant differences compared to the control group. However, while the lumbar region T-scores of those using duloxetine were within normal values, they were within the osteopenia range of venlafaxine and healthy controls.CONCLUSIONSNRIs may have a lower risk of developing osteoporosis than SSRIs. Of the SNRIs, duloxetine appears to be safer than venlafaxine. Further randomized controlled studies are warranted to determine whether SNRI use is risky.

01 Jan 2025·Journal of Pharmaceutical and Biomedical Analysis

MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients

Article

Author: Shang, Dewei ; Guo, Zhihao ; Zhang, Zi ; Huang, Shanqing ; Gan, Tongying

Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.

News (Medical) associated with Venlafaxine Hydrochloride

09 Oct 2024

·www.prnewswire.com

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Treatment with once-daily EFFEXOR® met primary and all secondary efficacy endpoints in outpatient adults with GAD EFFEXOR® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITTSBURGH and TOKYO, Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® (venlafaxine) in adults with generalized anxiety disorder (GAD). The study achieved its primary objective of superiority of anxiolytic effects of venlafaxine compared to placebo at 8 weeks, based on the change in the Hamilton Anxiety Rating Scale (HAM-A) total score from baseline (two-sided p-value=0.012). All seven secondary efficacy endpoints as defined by the trial protocol were met, which confirmed superiority compared to placebo. In this study, EFFEXOR® was generally well tolerated with a profile consistent with its known safety profile in non-Japanese patients. In particular: Low discontinuation rates due to treatment emergent adverse events (TEAEs) were seen (7.3% vs 1.7% in placebo) with 3.9% vs 0.6% assessed as related to treatment. No serious TEAEs or TEAEs with severe intensity were observed (0% vs 1.1% and 0.6%, respectively, in placebo). Incidence of new suicidal ideation was lower in the EFFEXOR® treatment group than in placebo (2.8% vs 5.1%). Commonly observed TEAEs like nausea and somnolence were reported at a lower rate than outside of Japan. "We are very pleased with these top-line results, which consistently demonstrate the efficacy and safety of EFFEXOR® for the treatment of generalized anxiety disorder in Japanese patients with moderate to severe disease. The benefit-risk profile observed with EFFEXOR® in this study underscores its potential as a meaningful treatment option for patients with GAD in Japan, a condition which currently does not have any approved treatments available," said Viatris Chief R&D Officer Philippe Martin. "This significant life cycle opportunity is yet another proof point of our diversified base business pipeline, which includes more than 70 novel products in development or under regulatory review. Our focused execution of this robust pipeline gives us confidence in our ability to continue to grow our base business and address unmet medical needs." "Despite generalized anxiety disorder being well-recognized globally, there is a large, general public awareness gap of GAD in Japan. Exacerbating this gap, is the absence of national clinical practice guidelines for treating the disease, signaling a large unmet need in Japan for those living with and treating excessive anxiety and worry," said Sun-A Kim, Country Manager of Viatris Japan. "Viatris Japan remains committed to meeting the needs of patients living with mental health disorders, and we are pleased to see that the results from this study signal the potential of EFFEXOR® to further reach patients as a possible treatment of GAD, for which there are currently no approved therapies in Japan." Outside of Japan, selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) are recommended as first-line drug therapies for patients diagnosed with GAD. EFFEXOR® is currently approved in Japan for the indication of major depressive disorder in adults. EFFEXOR® has also been approved for the indication of GAD in more than 80 countries outside of Japan. The Company expects to present the full results from this Phase 3 study at a future medical congress. About Phase 3 Study B2411367 The study was a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that was conducted in Japan to evaluate the efficacy and safety of venlafaxine in 357 Japanese outpatients with GAD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnostic criteria and assessed with a Hamilton Anxiety Rating Scale (HAM-A) total score ≥ 20. Patients were randomized equally to a flexible dose of 75-225 mg/day venlafaxine or placebo (once-daily, oral dosing) for an 8-week treatment period. The primary objective of the study was to show superiority over placebo in terms of the anxiolytic effects of venlafaxine, based on the change in the HAM-A total score from baseline at 8 weeks. The secondary objective was to evaluate the safety and tolerability of venlafaxine. Key secondary endpoints were defined as absolute score/change from baseline at 8 weeks in: HAM-A psychic anxiety factor HAM-A somatic anxiety factor Clinical Global Impressions-Severity of Illness (CGI-S) Clinical Global Impressions-Global Improvement (CGI-I) Generalized Anxiety Disorder 7 (GAD-7) Zung Self-Rating Anxiety Scale (ZSRAS) Sheehan Disability Scale (SDISS) Viatris is also conducting an open-label, multicenter, long-term extension (over 52 weeks) study to evaluate the safety and efficacy of venlafaxine in Japanese outpatients with GAD who completed study B2411367. Results from this study are scheduled to be delivered in 2025. About Generalized Anxiety Disorder (GAD) GAD is defined by the World Health Organization as persistent and excessive worry about daily activities or events. An estimated 4% of the global population currently experience an anxiety disorder.1 GAD is among the most prevalent and highly disabling mental health conditions that negatively impacts patient's quality of life and disrupts activities of daily living.2 About Viatris Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn , Instagram , YouTube and X (formerly Twitter). Forward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements regarding the outcomes of clinical trials; positive top-line results of its Phase 3 study (B2411367) in Japan evaluating the safety and efficacy of EFFEXOR® (venlafaxine) in adults with generalized anxiety disorder (GAD); Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025; the benefit-risk profile observed with EFFEXOR® in this study underscores its potential as a meaningful treatment option for patients with GAD in Japan, a condition which currently does not have any approved treatments available; this significant life cycle opportunity is yet another proof point of our diversified base business pipeline, which includes more than 70 novel products in development or under regulatory review; our focused execution of this robust pipeline gives us confidence in our ability to continue to grow our base business and address unmet medical needs; the Company expects to present the full results from this Phase 3 study at a future medical congress; Viatris is also conducting an open-label, multicenter, long-term extension (over 52 weeks) study to evaluate the safety and efficacy of venlafaxine in Japanese outpatients with generalized anxiety disorder who completed study B2411367 and results from this study are scheduled to be delivered in 2025. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; the possibility that Viatris may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that Viatris may be unable to achieve intended or expected benefits, goals, outlooks, synergies, growth opportunities and operating efficiencies in connection with divestitures, acquisitions, other transactions or restructuring programs, within the expected timeframes or at all; goodwill or impairment charges or other losses related to the divestiture or sale of businesses or assets; Viatris' failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. References World Health Organization. Anxiety Disorders Fact Sheet. 27 Sept. 2023, . Matsuyama S, Otsubo T, Nomoto K, Higa S, Takashio O. Prevalence of Generalized Anxiety Disorder in Japan: A General Population Survey. Neuropsychiatr Dis Treat. 2024;20:1355-1366. SOURCE Viatris Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Drug ApprovalPhase 2

01 Jul 2024

·www.drugs.com

Small Differences in Weight Change With First-Line Antidepressants

MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study published online July 2 in the Annals of Internal Medicine . Joshua Petimar, Sc.D., from Harvard Medical School and Harvard Pilgrim Health Care Institute in Boston, and colleagues conducted an observational cohort study over 24 months to compare weight change across common first-line antidepressant treatments using electronic health record data for 183,118 patients. Initiation of treatment with sertraline, citalopram, escitalopram, fluoxetine, paroxetine, bupropion, duloxetine, or venlafaxine was ascertained using prescription data. The researchers found that the estimated six-month weight gain was higher for escitalopram, paroxetine, duloxetine, venlafaxine, and citalopram than sertraline (differences, 0.41, 0.37, 0.34, 0.17, and 0.12 kg, respectively), was similar for fluoxetine (difference, −0.07 kg), and was lower for bupropion (difference, −0.22 kg). A 10 to 15 percent higher risk for gaining at least 5 percent of baseline weight was seen for escitalopram, paroxetine, and duloxetine, while a 15 percent reduced risk was seen for bupropion. Associations were stronger, with wider confidence intervals, when the effects of initiation and adherence were estimated. There was variation seen in six-month adherence, from 28 to 42 percent for duloxetine and bupropion, respectively. "Clinicians and patients could consider these differences when making decisions about specific antidepressants, especially given the complex relationships of obesity and depression with health, quality of life, and stigma," the authors write.

Clinical Result

01 Jul 2024

·www.sciencedaily.com

Weight change across common antidepressant medications

A new study compared weight change across eight common first-line antidepressants for patients taking an antidepressant for the first time. The study found differences in weight change between the different antidepressants after medication initiation, with bupropion consistently showing the least weight gain. The study adds rigorous evidence on expected weight gain across common antidepressant treatments. New evidence comparing weight gain under eight different first-line antidepressants finds that bupropion users are 15-20% less likely to gain a clinically significant amount of weight than users of sertraline, the most common medication. The findings are published July 2 in Annals of Internal Medicine. Antidepressants are among the most commonly prescribed medications in the U.S., with 14% of U.S. adults reporting using an antidepressant. Weight gain is a common side effect, which could affect patients' long-term metabolic health and cause some to stop taking their prescribed treatment, leading to poor clinical outcomes. Although antidepressants overall are associated with weight gain, specific antidepressant medications may affect weight differently. The new findings, led by investigators from the Harvard Pilgrim Health Care Institute reveal which common antidepressants are associated with the most and least weight gain following medication initiation. "Patients and their clinicians often have several options when starting an antidepressant for the first time. This study provides important real-world evidence regarding the amount of weight gain that should be expected after starting some of the most common antidepressants," said lead author Joshua Petimar, Harvard Medical School assistant professor of population medicine at the Harvard Pilgrim Health Care Institute. "Clinicians and patients can use this information, among other factors, to help decide on the right choice for them." Researchers used electronic health record prescription data from eight health systems in the U.S. participating in PCORnet, the National Patient-Centered Clinical Research Network, to conduct the study using data from 183,118 adults ages 18-80 years who were new users of antidepressants. While randomized control trials are considered the most rigorous method for comparing the effects of different medications, they are prohibitively costly and time consuming. In this case, the study team emulated a randomized trial by designing their ideal, hypothetical trial and aligning the data to match that trial as closely as possible. Study investigators compared weight at 6, 12, and 24 months after initiation of eight common antidepressants: sertraline, citalopram, escitalopram, fluoxetine, paroxetine, bupropion, duloxetine, and venlafaxine. Results showed that bupropion users gained the least amount of weight compared to users of other antidepressants. Bupropion users were approximately 15-20% less likely to gain a clinically significant amount of weight than those taking the most common medication, sertraline. The researchers considered weight gain of 5% or more as clinically significant. Results also showed a large percentage of patients were taking a medication that led to greater weight gain than alternatives that are commonly available in the same class or subclass. For example, sertraline, escitalopram, and paroxetine are all selective serotonin reuptake inhibitors (SSRI), the most common type of antidepressant, but escitalopram and paroxetine were each associated with an approximate 15% higher risk of gaining a clinically significant amount of weight than sertraline in the first 6 months. "Although there are several reasons why patients and their clinicians might choose one antidepressant over another, weight gain is an important side effect that often leads to patients stopping their medication," said senior author Jason Block, a general internal medicine physician and Harvard Medical School associate professor of population medicine at the Harvard Pilgrim Health Care Institute. "Our study found that some antidepressants, like bupropion, are associated with less weight gain than others. Patients and their clinicians could consider weight gain as one reason for choosing a medication that best fits their needs."

Clinical Result

100 Deals associated with Venlafaxine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00821	Venlafaxine Hydrochloride	N06AX16	DB00285

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anxiety Disorders	CA	BGP Pharma ULC	04 Mar 1998
Depressive Disorder, Major	CA	BGP Pharma ULC	04 Mar 1998
Panic Disorder	CA	BGP Pharma ULC	04 Mar 1998
Phobia, Social	CA	BGP Pharma ULC	04 Mar 1998
Depressive Disorder	CN	Chengdu Kanghong Pharmaceutical Group Co., Ltd.	01 Jan 1998
Generalized anxiety disorder	US	Upjohn US 2 LLC	20 Oct 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Generalized anxiety disorder	Discovery	ES	Viatris, Inc.	01 Mar 2005
Generalized anxiety disorder	Discovery	SE	Viatris, Inc.	01 Mar 2005
Generalized anxiety disorder	Discovery	NL	Viatris, Inc.	01 Mar 2005
Generalized anxiety disorder	Discovery	IT	Viatris, Inc.	01 Mar 2005
Generalized anxiety disorder	Discovery	CA	Viatris, Inc.	01 Mar 2005
Generalized anxiety disorder	Discovery	IE	Viatris, Inc.	01 Mar 2005
Depressive Disorder, Major	Discovery	CA	Wyeth Canada ULC	31 Dec 1994
Depressive Disorder	Discovery	US	Wyeth Pharmaceuticals LLC	28 Dec 1993

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04639193 (RESCUE-Combo, CTgov)	Phase 2	Sleep Apnea, Obstructive	20	Acetazolamide+Eszopiclone (Dual-Therapy)	edrbooqdlz(wpqphmaadr) = gjhqsrhnyp xipvnysoqz (vscijpqyqs, yvlwpzyhwu - oakjjcppjf) View more	-	02 May 2024
				Placebo+Acetazolamide+Eszopiclone (Placebo)	edrbooqdlz(wpqphmaadr) = yzmdaismdw xipvnysoqz (vscijpqyqs, wgczsqfqcj - owpupbswko) View more
NCT02977299 (ASCERTAIN-TRD, Pubmed) Manual	Phase 4	Depressive Disorder, Treatment-Resistant	260	Aripiprazole	(fxydpufhmo) = xzxkbbamuu odordzrbvh (hucntbymdr, 1.1) View more	Negative	07 Mar 2024
				Repetitive transcranial magnetic stimulation	(fxydpufhmo) = ocyuidtgcp odordzrbvh (hucntbymdr, 1.3) View more
Pubmed \| J Chromatogr A	Not Applicable	-	-	Agomelatine	jgibpljmjd(ntewnqpulu) = pdhfsbuytr coqdkinvob (zevlvfgygx ) View more	-	08 Nov 2023
				Venlafaxine	jgibpljmjd(ntewnqpulu) = bncptddgei coqdkinvob (zevlvfgygx ) View more
NCT00974155 (Pubmed \| J Clin Psychopharmacol)	Phase 4	Depressive Disorder, Major	234	Venlafaxine	cksmiyowwf(nhkisyqrej) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) anijnmxotg (irbyqulvsy ) View more	-	16 Nov 2020
NCT03588572 (CTgov)	Not Applicable	Aphasia \| Ischemic stroke	43	Venlafaxine hydrochloride capsules (Venlafaxine Group)	zlhltwgxvz(pxgyoiajwh) = xbkplkekux yqrvhewtzn (bjihquheji, krjliasmcp - rrrnejxbhx) View more	-	03 Oct 2019
				venlafaxine (Controlled Group)	zlhltwgxvz(pxgyoiajwh) = sbdbpitrbp yqrvhewtzn (bjihquheji, iqkfoltxja - bffmoqbuwq) View more
NCT01611155 (CTgov)	Not Applicable	Peripheral Nervous System Diseases \| Neuropathy	50	placebo	ojxbvesykl(aemxnuxbtv) = rrkzrckrmw yaidbqkwob (olswzzsfay, asdjnbryps - gxitiatoyo) View more	-	26 Sep 2019
NCT02407704 (MEDEX, CTgov)	Phase 4	Depressive Disorder, Major	31	Venlafaxine XR (Aerobic Exercise + Venlafaxine XR (60-79 Years of Age))	olasaotbeo(qkkomxsyzj) = itzsqhcuzl srxqyoyade (pmvazzwkdd, fmlhhkrxhf - rqczbmrbcb) View more	-	23 May 2018
				Venlafaxine XR (Venlafaxine XR Only (60-79 Years of Age))	olasaotbeo(qkkomxsyzj) = ospcdpetmh srxqyoyade (pmvazzwkdd, evdlpbncgv - zrplvihuuk) View more
P5.326 (AAN2018)	Phase 3	Fibromyalgia	163	Venlafaxine	pccyerxbiy(qmiurjgspm): P-Value = 0.033	Positive	10 Apr 2018
				Gabapentin
NCT01609348 (DIADs-3, CTgov)	Not Applicable	Alzheimer Disease \| Depressive Disorder	5	Venlafaxine (Venlafaxine)	cknyyfwltl(jeccehoveg) = btjqefxdqw cwztpnihti (auobjkvjcx, ypyfycpetr - ecwrkrggfk) View more	-	31 Jan 2018
				Placebo (Sugar Pill)	cknyyfwltl(jeccehoveg) = pbstargpna cwztpnihti (auobjkvjcx, fiyvrkohxs - ygkaazthgi) View more
NCT00354432 (CTgov)	Phase 3	Vasomotor symptom \| Hot Flashes \| Prostatic Cancer	120	Placebo Pill (Arm I - Placebo)	hxmuqgmaxg(ckddrhxnkw) = pgltpjlplo djuofjpxek (yfuibkuesq, tcrfwridmp - eghbyznbyg) View more	-	18 May 2017
				oral soy protein/isoflavones powder (Arm II - Soy)	hxmuqgmaxg(ckddrhxnkw) = eaolhoqmfl djuofjpxek (yfuibkuesq, iuknsoxexv - dytdofdtuy) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis